Natco Pharma Ltd

NSE: NATCOPHARM · BSE: 524816 · Pharmaceuticals & Biotechnology · 36 announcements

Share price: ₹810.90
Market cap: ₹15,907 Cr
Revenue (annual): ₹4,078 Cr
Net profit (annual): ₹1,418 Cr
P/E (TTM): 13.9×Sector 47.4×
Promoter holding: 49.42%+0.00% QoQ
FII holding: 16.99%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

25 Aug 2026 12:32 IST BSE

Natco Pharma Acquisition Worth ₹134 Cr

Natco Pharma Limited's subsidiaries will invest Rs 134.01 Crore in eGenesis, Inc., a US-based biotechnology company. The investment involves subscribing to 8% convertible promissory notes.

Value: ₹134.0 Cr

Read the filing ↗

25 Aug 2026 12:18 IST NSE

Acquisition

Natco Pharma Acquisition Worth ₹133 Cr

NATCO Pharma Limited is investing US$ 14 million (approx. ₹133 Crore) in eGenesis, Inc. via convertible promissory notes. This increases NATCO's total investment in the biotechnology firm to US$ 22 million.

Value: ₹133.0 Cr
Execution: September 30, 2026

Read the filing ↗